需机械通气的肌无力危象:250例多中心分析
该德国多中心回顾性研究分析2006至2015年间250例需机械通气的肌无力危象患者,中位年龄72岁、中位通气12天。高龄、晚发型、危象前高MGFA分级、合并症多、肺炎及复苏与延长通气相关;院内死亡率12%。
要点
- 高龄、晚发型、合并症多及肺炎与延长通气相关
- 血浆置换或免疫吸附作一线治疗可显著减少有创通气
- 预防并发症与神经重症监护是改善预后的关键
核心结论
- 肌无力危象的死亡率和通气时长与既往报道相当,尽管本研究患者年龄更高、疾病负担更重。
- 预防和处理并发症以及专业神经重症监护是改善结局的基石。
研究设计与样本
- 德国12个中心参与的回顾性研究,纳入2006至2015年间表现为肌无力危象的患者,共250例。
主要发现
- 危象时中位年龄72岁,机械通气中位时长12天,存活者中20.5%出院时仍需机械通气。
- 延长通气(>15天)与年龄(p=0.0001)、晚发型肌无力、危象前高MGFA分级(IVb:p=0.0001,OR为无穷大)、合并症>3项(p=0.002,OR 2.99)、肺炎(p=0.0001,OR 3.13)及复苏(p=0.0008,OR 9.15)相关。
- 早发型肌无力(p=0.0001,OR 0.21)、胸腺增生(p=0.002,OR 0)及无创通气试验成功者更可能通气<15天。
- 92例接受无创通气者中38%足以维持,且通气时长(p=0.001)和ICU住院时间(p=0.01)显著更短。
- 院内死亡率12%,与合并症>3项及急性呼吸窘迫综合征、复苏等并发症显著相关;主要死因为多器官衰竭,多由脓毒症所致。
关键数值与推荐
- 延长通气相关因素:年龄(p=0.0001)、晚发型MG、危象前MGFA IVb(p=0.0001,OR为无穷大)、合并症>3项(p=0.002,OR 2.99)、肺炎(p=0.0001,OR 3.13)、复苏(p=0.0008,OR 9.15)。
- 通气<15天的相关因素:早发型MG(p=0.0001,OR 0.21)、胸腺增生(p=0.002,OR 0)及无创通气试验成功。
- 以血浆置换或免疫吸附作为一线治疗者需有创通气的比例显著更低(p=0.003)。
- 通气与ICU住院时间延长时更可能序贯联合IVIG、血浆置换和免疫吸附(p=0.0503,OR 2.05)。
临床怎么用
- 对合并症多、肺炎或需复苏的肌无力危象患者应预判延长通气风险并加强监护。
- 可优先考虑血浆置换或免疫吸附作为一线治疗以减少有创通气需求。
- 对适宜患者尝试无创通气,成功者可缩短通气与ICU住院时间。
局限性
- 本研究为回顾性多中心分析,原文摘要未报告研究设计之外的局限性说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine demographic characteristics, clinical features, treatment regimens, and outcome of myasthenic crisis (MC) requiring mechanical ventilation (MV). METHODS: Analysis of patients who presented with MC between 2006 and 2015 in a German multicenter retrospective study. RESULTS: We identified 250 cases in 12 participating centers. Median age at crisis was 72 years. Median duration of MV was 12 days. Prolonged ventilation (>15 days) depended on age (p = 0.0001), late-onset myasthenia gravis (MG), a high Myasthenia Gravis Foundation of America Class before crisis (p = 0.0001 for IVb, odds ratio [OR] = infinite), number of comorbidities (>3 comorbidities: p = 0.002, OR 2.99), pneumonia (p = 0.0001, OR 3.13), and resuscitation (p = 0.0008, OR 9.15). MV at discharge from hospital was necessary in 20.5% of survivors. Patients with early-onset MG (p = 0.0001, OR 0.21), thymus hyperplasia (p = 0.002, OR 0), and successful noninvasive ventilation trial were more likely to be ventilated for less than 15 days. Noninvasive ventilation in 92 cases was sufficient in 38%, which was accompanied by a significantly shorter duration of ventilation (p = 0.001) and intensive care unit (ICU) stay (p = 0.01). IV immunoglobulins, plasma exchange, and immunoadsorption were more likely to be combined sequentially if the duration of MV and the stay in an ICU extended (p = 0.0503, OR 2.05). Patients who received plasma exchange or immunoadsorption as first-line therapy needed invasive ventilation significantly less often (p = 0.003). In-hospital mortality was 12%, which was significantly associated with the number of comorbidities (>3) and complications such as acute respiratory distress syndrome and resuscitation. Main cause of death was multiorgan failure, mostly due to sepsis. CONCLUSION: Mortality and duration of MC remained comparable to previous reports despite higher age and a high disease burden in our study. Prevention and treatment of complications and specialized neurointensive care are the cornerstones in order to improve outcome.
引用
- Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases. Neurology. 2019. PMID: 31801833. doi:10.1212/WNL.0000000000008688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。